The changing face of renal cell carcinoma pathology

Current Oncology Reports

Volumn 10, Issue 3, 2008, Pages 235-244

  Aydin, Hakan ^b   Zhou, Ming ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; B7 H1 ANTIGEN; B7 H4 ANTIGEN; CARBONATE DEHYDRATASE IX; GENE PRODUCT; PROTEIN IMP3; PROTEIN TFE3; SOMATOMEDIN B; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

BIRT HOGG DUBE SYNDROME; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER STAGING; CARCINOMA OF THE COLLECTING DUCT OF BELLINI; CHROMOSOME TRANSLOCATION X; CLEAR CELL CARCINOMA; DISEASE ASSOCIATION; FUHRMAN GRADING SYSTEM; GENE EXPRESSION PROFILING; GENE FUSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MULTILOCULAR CYSTIC RENAL CELL CARCINOMA; NEUROBLASTOMA; PROGNOSIS; RENAL MEDULLARY CARCINOMA; RENAL MUCINOUS TUBULAR AND SPINDLE CELL CARCINOMA; RENAL PAPILLARY CELL CARCINOMA; REVIEW; TUBEROUS SCLEROSIS; TUMOR DIFFERENTIATION; TUMOR NECROSIS; TUMOR VOLUME; VON HIPPEL LINDAU DISEASE; KIDNEY TUMOR; PATHOLOGY;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS;

EID: 58149136448     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0036-5     Document Type: Review

References (87)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: Pathology and Genetics, Tumors of the Urinary System and Male Genital Organs. Lyon: IAPC Press; 2004:9-88.
2. Suzigan S, López-Beltrán A, Montironi R, et al.: Multilocular cystic renal cell carcinoma: A report of 45 cases of a kidney tumor of low malignant potential. Am J Clin Pathol 2006, 125:217-222.
3. Antonelli A, Portesi E, Cozzoli A, et al.: The collecting duct carcinoma of the kidney: A cytogenetical study. Eur Urol 2003, 43:680-685.
4. Karakiewicz PI, Trinh QD, Rioux-Leclercq N, et al.: Collecting duct renal cell carcinoma: A matched analysis of 41 cases. Eur Urol 2007, 52:1140-1145.
5. Tokuda N, Naito S, Matsuzaki O, et al.: Collecting duct (Bellini duct) renal cell carcinoma: A nationwide survey in Japan. J Urol 2006, 176: 40-43; discussion 43.
6. Watanabe IC, Billis A, Guimaräes MS, et al.: Renal medullary carcinoma: Report of seven cases from Brazil. Mod Pathol 2007, 20:914-920.
7. Bell MD: Response to paclitaxel, gemictabine, and cisplatin in renal medullary carcinoma. Pediatr Blood Cancer 2006, 47:228.
8. Strouse JJ, Spevak M, Mack AK, et al.: Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 2005, 44:407-411.
9. Ferlicot S, Alorry Y, Compérat E, et al.: Mucinous tubular and spindle cell carcinoma: A report of 15 cases and a review of the literature. Virchows Arch 2005, 447:978-983.
10. Kuroda N, Toi M, Hiroi M, et al.: Review of mucinous tubular and spindle-cell carcinoma of the kidney with a focus on clinical and pathobiological aspects. Histol Histopathol 2005, 20:221-224.
11. Fine SW, Argani P, DeMarzo AM, et al.: Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney. Am J Surg Pathol 2006, 30:1554-1560.
12. Paner GP, Srigley JR, Radhakrishnan A, et al.: Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: Significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol 2006, 30:13-19.
13. Brandal P, Lie AK, Bassarova A, et al.: Genomic aberrations in mucinous tubular and spindle cell renal cell carcinomas. Mod Pathol 2006, 19:186-194.
14. Cossu-Rocca P, Eble JN, Delahunt B, et al.: Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Mod Pathol 2006, 19:488-493.
15. Argani P, Ladanyi M: Translocation carcinomas of the kidney. Clin Lab Med 2005, 25:363-378.
16. Argani P, Antonescu CR, Illei PB, et al.: Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: A distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001, 159:179-192.
17. Argani P, Olgac S, Tickoo SK, et al.: Xp11 translocation renal cell carcinoma in adults: Expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007, 31:1149-1160.
18. Meyer PN, Clark JI, Flanigan RC, Picken MM: Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol 2007, 128:70-79.
19. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM: The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007, 31:1578-1585.
20. Cohen D, Zhou M: Molecular genetics of familial renal cell carcinoma syndromes. Clin Lab Med 2005, 25:259-277.
21. Schmidt L, Duh FM, Chen F, et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73.
22. Launonen V, Vierimaa O, Kiuru M, et al.: Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001, 98:3387-3392.
23. Murakami T, Sano F, Huang Y, et al.: Identification and characterization of Birt-Hogg-Dube associated renal carcinoma. J Pathol 2007, 211:524-531.
24. Greene FL, Page DL, Fleming ID, et al.: AJCC Cancer Staging Handbook, 6th edn. New York: Springer; 2002.
25. Leibovich BC, Cheville JC, Lohse CM, et al.: A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. J Urol 2005, 174:1759-1763; discussion 1763.
26. Patard JJ, Leray E, Rioux-Leclercq N, et al.: Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol 2005, 23:2763-2771.
27. Sorbellini M, Kattan MW, Synder ME, et al.: A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005, 173:48-51.
28. Frank I, Blute ML, Leibovich BC, et al.: Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005, 173:1889-1892.
29. Hafez KS, Fergany AF, Novick AC: Nephron sparing surgery for localized renal cell carcinoma: Impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999, 162:1930-1933.
30. Ficarra V, Guillè F, Schips L, et al.: Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer 2005, 104:2116-21123.
31. Leibovich BC, Blute ML, Cheville JC, et al.: Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004, 171:1066-1070.
32. Patard JJ, Shvarts O, Lam JS, et al.: Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 2004, 171(Pt 1):2181-2185; quiz 2435.
33. Elmore JM, Kadesky KT, Koeneman KS, Sagalowsky AI: Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer 2003, 98:2329-2334.
34. Klatte T, Pattard JJ, Goel RH, et al.: Prognostic impact of tumor size on pT2 renal cell carcinoma: An international multicenter experience. J Urol 2007, 178:35-40; discussion 40.
35. Gilbert SM, Murphy AM, Katz AE, et al.: Reevaluation of TNM staging of renal cortical tumors: Recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology 2006, 68:287-291.
36. Gofrit ON, Shapiro A, Pizov G, et al.: Does stage T3a renal cell carcinoma embrace a homogeneous group of patients? J Urol 2007, 177:1682-1686.
37. Jeong IG, Jeong CW, Hong SK, et al.: Prognostic implication of capsular invasion without perinephric fat infiltration in localized renal cell carcinoma. Urology 2006, 67:709-712.
38. Klatte T, Chung J, Leppert JT, et al.: Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int 2007, 99:821-824.
39. Thomas DH, Verghese A, Kynaston HG, Griffiths DH: Analysis of the prognostic implications of different tumour margin types in renal cell carcinoma. Histopathology 2003, 43:374-380.
40. Thompson RH, Leibovich BC, Cheville JC, et al.: Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol 2005, 174(Pt 1):1218-1221.
41. Margulis V, Tamboli P, Matin SF, et al.: Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol 2007, 178:1878-1882.
42. Bonsib SM: The renal sinus is the principal iAvasive pathway: a prospective study of 100 renal cell carcinomas. Am J Surg Pathol 2004, 28:1594-1600.
43. Bonsib SM: T2 clear cell renal cell carcinoma iA a rare entity: a study of 120 clear cell renal cell carcinomas. J Urol 2005, 174(Pt 1):1199-1202; discussion 1202.
44. Ficarra V, Novara G, Iafrate M, et al.: Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol 2007, 51:722-729; discussion 729-731.
45. Thompson RH, Leibovich BC, Cheville JC, et al.: Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol 2005, 173:918-921.
46. Klatte T, Pantuck AJ, Riggs SB, et al.: Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol 2007, 178(Pt 1):1189-1195; discussion 1195.
47. Moinzadeh A, Libertino JA: Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 2004, 171(Pt 1):598-601.
48. Haferkamp A, Bastian PJ, Jakobi H, et al.: Renal cell carcinoma with tumor thrombus extension into the vena cava: Prospective long-term followup. J Urol 2007, 177:1703-1708.
49. Thompson RH, Cheville JC, Lohse CM, et al.: Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 2005, 104:53-60.
50. Terrone C, Cracco C, Porpiglia F, et al.: Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006, 49:324-331.
51. Cheville JC, Lohse CM, Zincke H, et al.: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003, 27:612-624.
52. Upton MP, Parker RA, Youmans A, et al.: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother (1197) 2005, 28: 488-495.
53. Novara G, Martignoni G, Artibani W, Ficarra V: Grading systems in renal cell carcinoma. J Urol 2007, 177:430-436.
54. Rioux-Leclercq N, Karakiewcz PI, Trinh QD, et al.: Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 2007, 109:868-874.
55. Lang H, Lindner V, de Fromont M, et al.: Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: Assessment of 241 patients with > 15-year follow-up. Cancer 2005, 103:625-629.
56. Sika-Paotonu D, Bethwaite PB, McCredie MR, et al.: Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol 2006, 30:1091-1096.
57. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al.: Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol 2007, 31:957-960.
58. de Peralta-Venturina M, Moch H, Amin M, et al.: Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases. Am J Surg Pathol 2001, 25:275-284.
59. Cheville JC, Lohse CM, Zincke H, et al.: Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004, 28:435-441.
60. Gökden N, Nappi O, Swanson PE, et al.: Renal cell carcinoma with rhabdoid features. Am J Surg Pathol 2000, 24:1329-1338.
61. Leroy X, Zini L, Buob D, et al.: Renal cell carcinoma with rhabdoid features: An aggressive neoplasm with overexpression of p53. Arch Pathol Lab Med 2007, 131:102-106.
62. Lam JS, Shvarts O, Said JW, et al.: Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 2005, 103:2517-2525.
63. Lee SE, Byun SS, Oh JK, et al.: Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma. J Urol 2006, 176(Pt 1):1332-1337; discussion 1337-1338.
64. Frank I, Blute ML, Cheville JC, et al.: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 2002, 168:2395-2400.
65. Uzzo RG, Cherullo EE, Myles J, Novick AC: Renal cell carcinoma invading the urinary collecting system: Implications for staging. J Urol 2002, 167:2392-2396.
66. Palapattu GS, Pantuck AJ, Dorey F, et al.: Collecting system invasion in renal cell carcinoma: Impact on prognosis and future staging strategies. J Urol 2003, 170:768-772; discussion 772.
67. Terrone C, Cracco C, Guercio S, et al.: Prognostic value of the involvement of the urinary collecting system in renal cell carcinoma. Eur Urol 2004, 46:472-476.
68. Antunes AA, Srougi M, Dall'Oglio MF, et al.: Microvascular invasion is an independent prognostic factor in patients with prostate cancer treated with radical prostatectomy. Int Braz J Urol 2006, 32:668-675; discussion 675-677.
69. Madbouly K, Al-Qahtani SM, Ghazwani Y, et al.: Microvascular tumor invasion: Prognostic significance in low-stage renal cell carcinoma. Urology 2007, 69:670-674.
70. Castilla EA, Liou LS, Abrahams NA, et al.: Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 2002, 60:993-997.
71. Sutherland SE, Resnick MI, Maclennan GT, Goldman HB: Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol 2002, 167:61-64.
72. Timsit MO, Bazin JP, Thiounn N, et al.: Prospective study of safety margins in partial nephrectomy: Intraoperative assessment and contribution of frozen section analysis. Urology 2006, 67:923-926.
73. Jiang Z: Prognostic biomarkers in renal cell carcinoma. Exp Rev Mol Diagn 2007, 7:293-307.
74. Bui MH, Seligson D, Han KR, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-811.
75. Atkins M, Regan M, McDermott D, et al.: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005, 11:3714-3721.
76. Leibovich BC, Sheinin Y, Lohse CM, et al.: Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007, 25:4757-4764.
77. Flies DP, Chen L: The new B7s: playing a pivotal role in tumor immunity. J Immunother (1997) 2007, 30:251-260.
78. Thompson RH, Kuntz SM, Leibovich BC, et al.: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66:3381-3385.
79. Krambeck AE, Thompson RH, Dong H, et al.: B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006, 103:10391-10396.
80. Jiang Z, Chu PG, Woda BA, et al.: Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: A retrospective study. Lancet Oncol 2006, 7:556-564.
81. Yin-Goen Q, Dale J, Yang WL, et al.: Advances in molecular classification of renal neoplasms. Histol Histopathol 2006, 21:325-339.
82. Yang XJ, Hutchinson PL, Johson CH, et al.: Classification of renal neoplasms based on molecular signatures. J Urol 2006, 175:2302-2306.
83. Furge KA, Lucas KA, Takahashi M, et al.: Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles. Cancer Res 2004, 64:4117-4121.
84. Takahashi M, Rhodes DR, Furge KA, et al.: Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001, 98:9754-9759.
85. Vasselli JR, Shih JH, Iyengar SR, et al.: Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A 2003, 100:6958-6963.
86. Furge KA, Tan MH, Dykema K, et al.: Identification of deregulated oncogenic pathways in renal cell carcinoma: An integrated oncogenomic approach based on gene expression profiling. Oncogene 2007, 26:1346-1350.
87. Chen YT, Fukuhara T, Tanaka M, et al.: Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res 2005, 11:58-66.